Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBITDA Margin (2016 - 2025)

CorMedix's EBITDA Margin history spans 14 years, with the latest figure at 0.07% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 7.0% year-over-year to 0.07%; the TTM value through Dec 2025 reached 0.03%, down 2.0%, while the annual FY2025 figure was 0.03%, 2.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 0.07% at CorMedix, down from 0.01% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 120199.83% in Q1 2023 and bottomed at 100446.94% in Q3 2022.
  • The 5-year median for EBITDA Margin is 34.62% (2024), against an average of 13952.93%.
  • The largest annual shift saw EBITDA Margin surged 21280594bps in 2023 before it crashed -12009157bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 13829.63% in 2021, then tumbled by -99bps to 27513.23% in 2022, then soared by 537bps to 120199.83% in 2023, then crashed by -100bps to 0.01% in 2024, then plummeted by -1137bps to 0.07% in 2025.
  • Per Business Quant, the three most recent readings for CRMD's EBITDA Margin are 0.07% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025).